Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Adhera Therapeutics - Key Facts

Adhera Therapeutics - Key Employees

Adhera Therapeutics - Key Employee Biographies

Adhera Therapeutics - Major Products and Services

Adhera Therapeutics - History

Adhera Therapeutics - Company Statement

Adhera Therapeutics - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Adhera Therapeutics - Business Description

Adhera Therapeutics - Corporate Strategy

Adhera Therapeutics - SWOT Analysis

SWOT Analysis - Overview

Adhera Therapeutics - Strengths

Adhera Therapeutics - Weaknesses

Adhera Therapeutics - Opportunities

Adhera Therapeutics - Threats

Adhera Therapeutics - Key Competitors

Section 3 – Company’s Lifesciences Financial Deals and Alliances

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Adhera Therapeutics, Recent Deals Summary

Section 4 – Company’s Recent Developments

Apr 04, 2019: Adhera Therapeutics appoints Nancy Phelan as Chief Executive Officer

Nov 20, 2018: Adhera Therapeutics selects IQVIA’s OCE technology platform to support commercial excellence

Nov 20, 2018: Adhera Therapeutics provides third quarter 2018 financial results and business update

Aug 06, 2018: Marina Biotech appoints Jay D. Schwartz to serve as senior vice president, commercial operations

Jun 29, 2018: Marina Biotech Names Uli Hacksell And Robert C. Moscato As Board Directors

Jun 20, 2018: Marina Biotech Appoints Robert Moscato to Chief Executive Officer

Section 5 – Appendix

Methodology

About GlobalData

Contact Us

Disclaimer

Adhera Therapeutics (ATRX) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

Adhera Therapeutics (Adhera) is a biopharmaceutical company that leverages technologies to commercialize unique therapies in improving the patient outcomes. Its flagship product Prestalia is a fixed dose combination of perindopril arginine and amlodipine besylate. Prestalia is approved by the US-FDA and is used in the treatment of hypertension to lower blood pressure. Prestalia is sold under the brand name Coveram or Viacoram outside the US. The company also offers Total Care System through its DyrctAxess patented technology platform. Adhera sells products through wholesale pharmaceutical distributors and pharmacies. Adhera is headquartered in Durham, North Carolina, the US.

Adhera Therapeutics Key Recent Developments

Apr 04,2019: Adhera Therapeutics appoints Nancy Phelan as Chief Executive Officer
Nov 20,2018: Adhera Therapeutics selects IQVIA’s OCE technology platform to support commercial excellence
Nov 20,2018: Adhera Therapeutics provides third quarter 2018 financial results and business update
Aug 06,2018: Marina Biotech appoints Jay D. Schwartz to serve as senior vice president, commercial operations
Jun 29,2018: Marina Biotech Names Uli Hacksell And Robert C. Moscato As Board Directors

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.